Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy weight-loss drug four years ago,

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions